Engineering immune cell therapies for inflammatory bowel disease: from stem cells to CAR T cells.

CAR T cell therapy targeting CD19 can induce long-term remission of intestinal inflammation in ulcerative colitis, revealing a new therapeutic avenue for IBD.

• Why it matters: Effective management of inflammatory bowel disease remains difficult despite existing treatments, highlighting the need for innovative and targeted cellular therapies to improve patient outcomes.
• What they did: The study reviews emerging cellular immunotherapies, including stem cell approaches, regulatory T cell therapies, and CAR T cell platforms, with early clinical trials showing promising results.
• The result: Findings suggest CAR T cell strategies could transform IBD treatment by targeting mucosal B cells, but rigorous clinical trials are necessary to confirm safety and efficacy.